1-benzyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid | 881693-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-benzyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid
• 英文别名: 2-benzyl-5-trifluoromethyl-2H-pyrazole-3-carboxylic acid；2-benzyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid
• CAS: 881693-05-6
• 化学式: C₁₂H₉F₃N₂O₂
• 分子量: 270.211
• InChiKey: MRRLYNMNEMPYBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-benzyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Potent Non-Nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase Complex

  摘要：

  Measles virus (MV) is one of the most infectious pathogens known. In spite of the existence of a vaccine, approximately 350000 deaths/year result from MV or associated complications. Antimeasles compounds Could conceivably diminish these statistics and provide a therapy that complements vaccine treatment. We recently described a high-throughput screening hit compound 1 (16677) against MV-infected cells with the capacity to eliminate viral reproduction at 250 nM by inhibiting the action of the virus's RNA-dependent RNA polymerase complex (RdRp). The compound, 1-methyl-3-(trifluoroi-nethyl)-N-[4-sulfonylphenyl]-1H-pyrazole-5-carboxamide, 1 carries a critical CF3 moiety on the 1,2-pyrazole ring. Elaborating on the preliminary structure-activity (SAR) study, the present work presents the synthesis and SAR of a much broader range of low nanomolar nonpeptidic MV inhibitors and speculates on the role of the CF3 functionality.

  DOI：

  10.1021/jm701239a
• 作为产物：
  描述：

  溴甲苯 在 lithium hydroxide monohydrate 、 水 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 1-benzyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid
  参考文献：
  名称：

  [EN] KCNT1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION

  摘要：

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因（例如KCNT1）中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因如KCNT1中的功能增强突变的方法。

  公开号：

  WO2020227101A1

文献信息

• Tricycles, their manufacture and use as pharmaceutical agents
  申请人：Guy Georges

  公开号：US20060069145A1

  公开（公告）日：2006-03-30

  The present invention relates to compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明涉及公式I化合物及其药用可接受的盐、对映体形式、非对映异构体和混合物，上述化合物的制备，含有它们的药物以及其制造，以及上述化合物在控制或预防癌症等疾病中的用途。
• Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents
  申请人：Georges Guy

  公开号：US20090143375A1

  公开（公告）日：2009-06-04

  Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.

  本发明的对象是公式I的化合物及其药学上可接受的盐、对映体、非对映异构体和混合物，上述化合物的制备，含有它们的药物以及它们的制造，以及上述化合物在控制或预防癌症等疾病方面的应用。
• WO2007/68465
  申请人：——

  公开号：——

  公开（公告）日：——
• TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
  申请人：F. Hoffmann-Roche AG

  公开号：EP1793822A1

  公开（公告）日：2007-06-13
• TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1966213A1

  公开（公告）日：2008-09-10